AAPL295.21+0.91 (+0.31%) ▲|ABBV234.90+0.14 (+0.06%) ▲|ABT91.32+0.79 (+0.87%) ▲|ACN130.73+3.72 (+2.93%) ▲|ADBE198.34+0.91 (+0.46%) ▲|AMAT573.95-11.93 (-2.04%) ▼|AMD511.33-8.52 (-1.64%) ▼|AMGN352.94+5.93 (+1.71%) ▲|AMT175.64-3.75 (-2.09%) ▼|AMZN237.47+3.36 (+1.44%) ▲|AVGO380.41+0.26 (+0.07%) ▲|AXP343.84+6.06 (+1.79%) ▲|BA221.80+5.09 (+2.35%) ▲|BAC57.78-0.14 (-0.23%) ▼|BKNG184.57+15.63 (+9.25%) ▲|BLK991.34-23.99 (-2.36%) ▼|BMY55.29-0.24 (-0.43%) ▼|BNY144.79-2.50 (-1.70%) ▼|BRK-B496.73+3.92 (+0.80%) ▲|C144.09-0.88 (-0.61%) ▼|CAT982.68-1.56 (-0.16%) ▼|CL92.55+1.12 (+1.23%) ▲|CMCSA22.74-0.06 (-0.26%) ▼|COF202.20+4.39 (+2.22%) ▲|COP106.86-3.11 (-2.83%) ▼|COST964.38+6.70 (+0.70%) ▲|CRM153.65+0.23 (+0.15%) ▲|CSCO119.54-1.61 (-1.33%) ▼|CVS101.28-0.29 (-0.29%) ▼|CVX171.73-4.25 (-2.42%) ▼|DE607.88+15.94 (+2.69%) ▲|DHR189.21+10.24 (+5.72%) ▲|DIS102.41-1.12 (-1.09%) ▼|DUK125.90+0.85 (+0.68%) ▲|EMR141.90-1.24 (-0.87%) ▼|FDX312.59-4.65 (-1.47%) ▼|GD346.77-3.57 (-1.02%) ▼|GE367.44+10.97 (+3.08%) ▲|GEV1,054.15+19.17 (+1.85%) ▲|GILD125.99+0.94 (+0.75%) ▲|GM79.72+0.77 (+0.98%) ▲|GOOG344.16-1.92 (-0.55%) ▼|GOOGL344.59-1.50 (-0.43%) ▼|GS1,078.79-15.65 (-1.43%) ▼|HD342.12+17.67 (+5.45%) ▲|HON228.14+5.77 (+2.59%) ▲|IBM263.80-1.15 (-0.43%) ▼|INTC129.95-2.33 (-1.76%) ▼|INTU267.57+9.52 (+3.69%) ▲|ISRG403.71+0.53 (+0.13%) ▲|JNJ240.10+1.02 (+0.43%) ▲|JPM333.51-0.63 (-0.19%) ▼|KO81.04+0.73 (+0.90%) ▲|LIN518.89+6.63 (+1.29%) ▲|LLY1,113.06+5.98 (+0.54%) ▲|LMT497.05-6.63 (-1.32%) ▼|LOW221.64+8.10 (+3.79%) ▲|LRCX363.79-7.54 (-2.03%) ▼|MA496.59+8.52 (+1.74%) ▲|MCD275.21+3.55 (+1.31%) ▲|MDLZ62.14+1.08 (+1.76%) ▲|MDT80.67+0.04 (+0.05%) ▲|META559.97-2.23 (-0.40%) ▼|MMM166.67+4.83 (+2.98%) ▲|MO72.09+0.48 (+0.67%) ▲|MRK121.12+1.52 (+1.27%) ▲|MS221.08-4.95 (-2.19%) ▼|MSFT370.44-3.50 (-0.94%) ▼|MU1,020.95-30.82 (-2.93%) ▼|NEE87.19+0.76 (+0.87%) ▲|NFLX72.74-0.09 (-0.12%) ▼|NKE41.81-0.57 (-1.35%) ▼|NOW94.11-1.84 (-1.91%) ▼|NVDA197.75-2.26 (-1.13%) ▼|ORCL156.41-8.75 (-5.30%) ▼|PEP142.83+0.78 (+0.55%) ▲|PFE24.08-0.65 (-2.61%) ▼|PG152.80+1.94 (+1.29%) ▲|PLTR113.73-2.97 (-2.54%) ▼|PM178.63-0.07 (-0.04%) ▼|QCOM194.44-9.69 (-4.75%) ▼|RTX186.70+0.31 (+0.17%) ▲|SBUX104.57+3.52 (+3.48%) ▲|SCHW91.65-1.52 (-1.63%) ▼|SO95.21+0.28 (+0.30%) ▲|SPG221.68+4.94 (+2.28%) ▲|T22.49-0.32 (-1.41%) ▼|TMO491.05+21.70 (+4.62%) ▲|TMUS183.20-1.37 (-0.74%) ▼|TSLA375.83-5.78 (-1.51%) ▼|TXN303.20-1.16 (-0.38%) ▼|UBER73.94+4.27 (+6.12%) ▲|UNH404.54-4.71 (-1.15%) ▼|UNP260.22+1.61 (+0.62%) ▲|UPS105.09-0.74 (-0.70%) ▼|USB60.19+0.14 (+0.22%) ▲|V333.19+4.71 (+1.43%) ▲|VZ45.85-0.88 (-1.88%) ▼|WFC84.37+0.24 (+0.28%) ▲|WMT119.78+0.36 (+0.30%) ▲|XOM136.34-3.39 (-2.43%) ▼|AAPL295.21+0.91 (+0.31%) ▲|ABBV234.90+0.14 (+0.06%) ▲|ABT91.32+0.79 (+0.87%) ▲|ACN130.73+3.72 (+2.93%) ▲|ADBE198.34+0.91 (+0.46%) ▲|AMAT573.95-11.93 (-2.04%) ▼|AMD511.33-8.52 (-1.64%) ▼|AMGN352.94+5.93 (+1.71%) ▲|AMT175.64-3.75 (-2.09%) ▼|AMZN237.47+3.36 (+1.44%) ▲|AVGO380.41+0.26 (+0.07%) ▲|AXP343.84+6.06 (+1.79%) ▲|BA221.80+5.09 (+2.35%) ▲|BAC57.78-0.14 (-0.23%) ▼|BKNG184.57+15.63 (+9.25%) ▲|BLK991.34-23.99 (-2.36%) ▼|BMY55.29-0.24 (-0.43%) ▼|BNY144.79-2.50 (-1.70%) ▼|BRK-B496.73+3.92 (+0.80%) ▲|C144.09-0.88 (-0.61%) ▼|CAT982.68-1.56 (-0.16%) ▼|CL92.55+1.12 (+1.23%) ▲|CMCSA22.74-0.06 (-0.26%) ▼|COF202.20+4.39 (+2.22%) ▲|COP106.86-3.11 (-2.83%) ▼|COST964.38+6.70 (+0.70%) ▲|CRM153.65+0.23 (+0.15%) ▲|CSCO119.54-1.61 (-1.33%) ▼|CVS101.28-0.29 (-0.29%) ▼|CVX171.73-4.25 (-2.42%) ▼|DE607.88+15.94 (+2.69%) ▲|DHR189.21+10.24 (+5.72%) ▲|DIS102.41-1.12 (-1.09%) ▼|DUK125.90+0.85 (+0.68%) ▲|EMR141.90-1.24 (-0.87%) ▼|FDX312.59-4.65 (-1.47%) ▼|GD346.77-3.57 (-1.02%) ▼|GE367.44+10.97 (+3.08%) ▲|GEV1,054.15+19.17 (+1.85%) ▲|GILD125.99+0.94 (+0.75%) ▲|GM79.72+0.77 (+0.98%) ▲|GOOG344.16-1.92 (-0.55%) ▼|GOOGL344.59-1.50 (-0.43%) ▼|GS1,078.79-15.65 (-1.43%) ▼|HD342.12+17.67 (+5.45%) ▲|HON228.14+5.77 (+2.59%) ▲|IBM263.80-1.15 (-0.43%) ▼|INTC129.95-2.33 (-1.76%) ▼|INTU267.57+9.52 (+3.69%) ▲|ISRG403.71+0.53 (+0.13%) ▲|JNJ240.10+1.02 (+0.43%) ▲|JPM333.51-0.63 (-0.19%) ▼|KO81.04+0.73 (+0.90%) ▲|LIN518.89+6.63 (+1.29%) ▲|LLY1,113.06+5.98 (+0.54%) ▲|LMT497.05-6.63 (-1.32%) ▼|LOW221.64+8.10 (+3.79%) ▲|LRCX363.79-7.54 (-2.03%) ▼|MA496.59+8.52 (+1.74%) ▲|MCD275.21+3.55 (+1.31%) ▲|MDLZ62.14+1.08 (+1.76%) ▲|MDT80.67+0.04 (+0.05%) ▲|META559.97-2.23 (-0.40%) ▼|MMM166.67+4.83 (+2.98%) ▲|MO72.09+0.48 (+0.67%) ▲|MRK121.12+1.52 (+1.27%) ▲|MS221.08-4.95 (-2.19%) ▼|MSFT370.44-3.50 (-0.94%) ▼|MU1,020.95-30.82 (-2.93%) ▼|NEE87.19+0.76 (+0.87%) ▲|NFLX72.74-0.09 (-0.12%) ▼|NKE41.81-0.57 (-1.35%) ▼|NOW94.11-1.84 (-1.91%) ▼|NVDA197.75-2.26 (-1.13%) ▼|ORCL156.41-8.75 (-5.30%) ▼|PEP142.83+0.78 (+0.55%) ▲|PFE24.08-0.65 (-2.61%) ▼|PG152.80+1.94 (+1.29%) ▲|PLTR113.73-2.97 (-2.54%) ▼|PM178.63-0.07 (-0.04%) ▼|QCOM194.44-9.69 (-4.75%) ▼|RTX186.70+0.31 (+0.17%) ▲|SBUX104.57+3.52 (+3.48%) ▲|SCHW91.65-1.52 (-1.63%) ▼|SO95.21+0.28 (+0.30%) ▲|SPG221.68+4.94 (+2.28%) ▲|T22.49-0.32 (-1.41%) ▼|TMO491.05+21.70 (+4.62%) ▲|TMUS183.20-1.37 (-0.74%) ▼|TSLA375.83-5.78 (-1.51%) ▼|TXN303.20-1.16 (-0.38%) ▼|UBER73.94+4.27 (+6.12%) ▲|UNH404.54-4.71 (-1.15%) ▼|UNP260.22+1.61 (+0.62%) ▲|UPS105.09-0.74 (-0.70%) ▼|USB60.19+0.14 (+0.22%) ▲|V333.19+4.71 (+1.43%) ▲|VZ45.85-0.88 (-1.88%) ▼|WFC84.37+0.24 (+0.28%) ▲|WMT119.78+0.36 (+0.30%) ▲|XOM136.34-3.39 (-2.43%) ▼|
27.5 C
New York
Wednesday, June 24, 2026

Tag: study

newssourceFORcompanyinformationcontent1marketreleases

Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis

Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas, July 22, 2025 /PRNewswire/ -- Caris Life...

Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology

New research paper highlights the unique structure and function of Nanoscope's synthetic opsin, supporting its potential in vision restoration DALLAS, July 22, 2025 /PRNewswire/...

Giyani Announces Non-Brokered Private Placement

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, July 22, 2025 /CNW/ - Giyani Metals Corp. (TSXV:...

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

Jacobs to Support Critical Ireland Railway Infrastructure Program

Route modernization and expansion enabling greater regional accessibility Key regional and intercity corridor upgrade project commences DALLAS, July 22, 2025 /PRNewswire/ -- Jacobs (NYSE: J) has been...

SkylineDx’s Merlin Melanoma Assay shows its ability to reduce SLNB by over 40% in a Danish Multicenter Validation Study

In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery...

SkylineDx’s Merlin Melanoma Assay shows its ability to reduce SLNB by over 40% in a Danish Multicenter Validation Study

In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery...

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

SNACKS, PEP TALKS, AND SECRET CRIES: SURVEY REVEALS WHAT AUSTRALIANS REALLY DO IN THEIR CARS

BRISBANE, Australia, July 22, 2025 /PRNewswire/ -- New research released today from insurance provider Youi has revealed that for many Australians, their car is...

[Latest] Global Naphthalene Sulfonate Market Size/Share Worth USD 1,113.50 Million by 2034 at a 3.16% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends,...

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Naphthalene Sulfonate Market size & share revenue was valued at approximately USD 813.20 Million in 2024 and is expected to reach USD 841.78 Million in 2025 and is expected to reach around USD 1,113.50 Million by 2034, at a CAGR of 3.16% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Acar Kimya, Akzo Nobel N.V., BASF SE, Enaspol, GCP Applied Technologies Inc., Giovanni Bozzetto S.p.A., Himadri Speciality Chemical Limited, Hunstman International LLC, Kao Corporation, Koppers Inc., MUHU (China) Construction Materials Company Limited, Nease Performance Chemicals, PCC SE, Arkema Group, and Eastman Chemical Company and others. 
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Naphthalene Sulfonate Market size & share revenue was valued at approximately USD 813.20 Million in 2024 and is expected to reach USD 841.78 Million in 2025 and is expected to reach around USD 1,113.50 Million by 2034, at a CAGR of 3.16% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Acar Kimya, Akzo Nobel N.V., BASF SE, Enaspol, GCP Applied Technologies Inc., Giovanni Bozzetto S.p.A., Himadri Speciality Chemical Limited, Hunstman International LLC, Kao Corporation, Koppers Inc., MUHU (China) Construction Materials Company Limited, Nease Performance Chemicals, PCC SE, Arkema Group, and Eastman Chemical Company and others.

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

CHAMPION IRON ENTERS INTO A DEFINITIVE AGREEMENT WITH NIPPON STEEL AND SOJITZ TO FORM A PARTNERSHIP FOR THE KAMI PROJECT

MONTRÉAL, July 21, 2025 /CNW/ - SYDNEY, July 22, 2025 - Champion Iron Limited (TSX: CIA) (ASX: CIA) (OTCQX: CIAFF) ("Champion" or the "Company") announces...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers